Amphastar Pharmaceuticals Inc vs TG Therapeutics Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.04 (market cap $868.62M), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 8.8× Amphastar Pharmaceuticals Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TGTX | |
|---|---|---|
Market Cap | $868.62M | $7.64B |
Sector | Health | Health |
52-Week High | $30.81 | $59.06 |
52-Week Low | $16.87 | $26.94 |
Enterprise Value | $1.27B | $7.84B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.86, down 2.22% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
Outlook is cautious due to recent earnings misses and regulatory scrutiny, including an FDA warning letter. Analyst consensus leans Hold (66.67%) with limited Buy support. Key risks include competitive pressures and potential tariff impacts on generic drugs. Cash flow trends improved in 2026 with net cash flow rising to $36 million.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →